By M. Marin
NASDAQ:SBC
READ THE FULL SBC RESEARCH REPORT
Company positive about impact of new service offerings, pricing revisions, other measures
SBC Medical Group Holdings (NASDAQ:SBC), which provides end-to-end solutions enabling aesthetics clinics to launch, expand and/or operate their businesses, reported 2Q25 results last week. Revenue of $43.4 million declined from $53.1 million in 2Q24.
The lower year-over-year results were expected, as management has previously remarked on ongoing headwinds that SBC is working to overcome, with multiple organic strategies to counter intensifying competition in Japan's aesthetic medicine market, as new competitors have entered the market. For example, the company has launched a multi-brand strategy to address the increasingly diverse needs of its growing customer base. By customizing services across multiple brands, the company expects to segment the market and garner more market share overall.
Historically, SBC’s primary area of focus has been aesthetic medicine, but the company is diversifying to support a broader range of franchisee services, which SBC expects will strengthen its position and market share within the aesthetic and specialized medical care areas. Clinics in the SBC franchise network have expanded their offerings to encompass a broad range of specialized medical services, including plastic surgery and infertility treatment. Other medical services that the company is focused on include orthopedics, ophthalmology, infertility, and health treatment, in addition to aesthetic medicine. SBC believes this will create a holistic offering that appeals to a broad range of patient needs.
MB career lounge expected to strengthen market position
The company intends to strengthen its market position both through organic measures and strategic M&A. For example, the company acquired MB career lounge, which provides management support services for medical institutions and specializes in consulting, training, and human resources solutions in Japan. SBC expects the acquisition will enhance its management support service offerings. As a result of the acquisition, JUN Clinics – which operates six clinics – joined the SBC network.
Moreover, the company appointed a new Chief Marketing Officer (CMO), effective July 1, 2025, to raise awareness of its growing portfolio of brands. The company is optimistic that its revised pricing, promotional and fee strategies will support strong growth over time, despite some potential short-term constraint. For example, the company adjusted pricing upward for certain services characterized by high demand, such as medical hair services, as that market consolidates. The company is optimistic that this represents a source of growth for SBC with substantial upside potential, as currently only about 9% of adult men utilize these services, but a growing number of men are increasingly interested in aesthetic procedures, particularly for hair replenishment.
The company is also optimistic about generating new / growing revenue streams from international customers, both through greater outreach to medical tourists and by expanding its global footprint. SBC is encouraged by results at its existing international operations and recently appointed Dr. Steven R. Cohen as Medical Strategy Advisor to help advance its global expansion strategy. He is based in California, has more than 30 years of clinical experience, has published many scientific papers and textbooks, and is also a Clinical Professor at the University of California, San Diego. SBC intends to expand further in existing and potentially additional international and domestic markets.
Solid cash position expected to give SBC flexibility to pursue strategic growth opportunities
The company remains in a strong financial position with a solid cash balance and minimum debt. The company ended 2Q25 with cash and equivalents of $152.7 million, compared to $125 million at year-end 2024. This is expected to give SBC the flexibility to pursue strategic growth opportunities. The company intends to allocate available capital to organic and strategic M&A investments in Japan and internationally.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.